Proteintech and HebeCell announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases.
Ankarys Therapeutics Inc. (Ankarys), Applied StemCell, Inc. (ASC), and HebeCell Corp. (HebeCell) announced that they have entered into a strategic collaboration to co-develop allogeneic induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) NK cell therapeutics targeting hematological malignancies.
HebeCell Corp (“HebeCell”) today announced that it has closed a US$10 million Pre-Series A financing to further advance the research and development of its leading patented scalable natural killer (NK) cell platform technology. Aceso Biotech Venture Fund invested in this round of financing.
HebeCell will attend the Phacilitate Leaders World & World Stem Cell Summit 2020 as an associate sponsor from January 21-24, 2020 in Miami.
As our understanding of stem cell biology surges forward, new investigational therapies are rapidly advancing towards and through clinical trials. This special Toronto event “From Stem Cell Biology to New Therapies” will highlight current clinical applications of stem cell therapies. The program features world-renowned leaders in translational research from academia and industry, and will include an interactive panel that will discuss the regulatory challenges of translational stem cell research.